Quench 1% Cream 15GM (silver sulphadiazine): Uses, Dosage & Side Effects

What it's for (Indications)

Silver sulfadiazine cream is indicated as a topical antimicrobial agent for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
Its broad spectrum of antimicrobial activity encompasses a wide range of gram-positive and gram-negative bacteria, as well as some yeasts, which are common pathogens found in burn wounds.
This comprehensive coverage is crucial for managing burn wounds, which are highly susceptible to bacterial colonization and subsequent infection.
Early and effective treatment is paramount to reduce the incidence of complications such as cellulitis, invasive sepsis, and delayed wound healing, ultimately improving patient outcomes and survival rates in severe burn cases.
The continuous application of silver sulfadiazine creates a protective barrier against pathogenic microorganisms, facilitating a cleaner wound environment conducive to healing.

Dosage Information

Type	Guideline
Standard	Silver sulfadiazine cream is intended for topical application only. After cleansing and debridement of the burn wound, the cream should be applied aseptically to the affected areas once or twice daily, to a thickness of approximately 1/16 inch (1.5 mm). The burn wound should be covered with the cream at all times. If a dressing is applied, it should be changed daily to maintain optimal wound care. Treatment should continue until the wound is healed sufficiently for autografting, or until the wound is deemed ready for permanent closure. The duration of therapy can vary significantly depending on the extent and depth of the burn, as well as the patient's individual response, requiring careful clinical judgment and patient monitoring. A thin, continuous layer ensures maximal antimicrobial effect and wound protection, which is vital for preventing infection.

Type

Guideline

Standard

Silver sulfadiazine cream is intended for topical application only. After cleansing and debridement of the burn wound, the cream should be applied aseptically to the affected areas once or twice daily, to a thickness of approximately 1/16 inch (1.5 mm). The burn wound should be covered with the cream at all times. If a dressing is applied, it should be changed daily to maintain optimal wound care. Treatment should continue until the wound is healed sufficiently for autografting, or until the wound is deemed ready for permanent closure. The duration of therapy can vary significantly depending on the extent and depth of the burn, as well as the patient's individual response, requiring careful clinical judgment and patient monitoring. A thin, continuous layer ensures maximal antimicrobial effect and wound protection, which is vital for preventing infection.

Safety & Warnings

Common Side Effects

The most frequently reported local adverse reactions to silver sulfadiazine include transient pain, burning sensation, and itching at the application site.
Systemic adverse reactions, though less common due to topical administration, can occur due to systemic absorption of the sulfonamide component.
The most common serious systemic reaction is transient leukopenia, characterized by a decrease in white blood cell count, typically occurring between 2 to 4 days after initiation of treatment and usually resolving spontaneously despite continued therapy.
Other potential systemic effects include rash, erythema multiforme, skin discoloration (argyria with prolonged exposure to silver), crystalluria, renal tubular necrosis, interstitial nephritis, hepatic dysfunction, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and methemoglobinemia.
Hematological effects such as aplastic anemia, agranulocytosis, and hemolytic anemia (especially in G6PD deficient individuals) have also been reported, necessitating vigilant monitoring.

Serious Warnings

Black Box Warning: **SERIOUS WARNINGS: POTENTIAL FOR SYSTEMIC ABSORPTION AND SULFONAMIDE-ASSOCIATED ADVERSE REACTIONS** Despite being a topical agent, significant systemic absorption of the sulfadiazine component can occur, particularly when applied to large surface areas, extensive burns, or for prolonged periods. This systemic absorption carries the risk of sulfonamide-associated adverse reactions. **Therefore, silver sulfadiazine is contraindicated in premature infants and full-term neonates less than two months of age due to the substantial risk of kernicterus.** Sulfonamides can displace bilirubin from albumin, increasing free bilirubin levels and the risk of severe neurotoxicity in infants with immature hepatic metabolic pathways. **It is also contraindicated in pregnant women at or near term (third trimester)** for the same reason, given the potential for systemic absorption and subsequent fetal exposure. **Hematological Adverse Reactions:** The most frequent serious adverse reaction reported with silver sulfadiazine is transient leukopenia, often observed within the first few days of treatment. Other potentially severe hematological effects, including aplastic anemia, agranulocytosis, and hemolytic anemia (especially in G6PD deficient individuals), have been reported. **Hypersensitivity Reactions:** Patients with known hypersensitivity to sulfonamides may experience cross-sensitivity reactions, including severe dermatological reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis, or other allergic manifestations. Close monitoring of blood counts, renal function, and liver function is imperative, especially in at-risk populations or during extensive usage.
Due to potential systemic absorption of the sulfadiazine component, caution is advised in patients with impaired renal or hepatic function, as accumulation and increased toxicity may occur.
Silver sulfadiazine should be used with extreme caution in patients with known sulfonamide hypersensitivity, as cross-sensitivity may occur, potentially leading to severe allergic reactions.
The possibility of systemic absorption means that effects such as leukopenia, renal impairment, and hepatic dysfunction require vigilant monitoring, particularly in patients with extensive burns or during prolonged treatment.
Additionally, patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are at increased risk of hemolytic anemia.
It is crucial to monitor complete blood counts (CBCs), renal function tests, and liver function tests, especially during prolonged treatment or application to large surface areas, to detect early signs of systemic toxicity.
Avoid application to the eyes.

How it Works (Mechanism of Action)

Silver sulfadiazine exerts its antimicrobial action through a dual mechanism involving both the silver moiety and the sulfadiazine component. The silver component, released as silver ions, primarily acts on the bacterial cell membrane and cell wall, disrupting their integrity and permeability, thereby interfering with vital cellular processes such as respiration and transport. It also binds to bacterial DNA, inhibiting replication and transcription, ultimately leading to bacterial cell death. The sulfadiazine component, a sulfonamide, competitively inhibits dihydropteroate synthase, an enzyme crucial for the synthesis of dihydrofolic acid, which is a precursor to tetrahydrofolic acid. Tetrahydrofolic acid is essential for bacterial DNA, RNA, and protein synthesis. This combined action provides broad-spectrum antibacterial efficacy against a wide range of gram-positive and gram-negative organisms commonly found in burn wound infections, including *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Enterobacter cloacae*, significantly reducing bacterial burden.